Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATLAS: Selonsertib, Firsocostat, and Cilofexor in Advanced NASH
NCT03449446Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Mar 2018
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of selonsertib, firsocostat, cilofexor in Nonalcoholic steatohepatitis (NASH), sponsored by Gilead Sciences. Started Mar 2018; status: completed.
02
Drugs
selonsertibfirsocostatcilofexor
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03449446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03449446.